Brian A. Millen

2.1k citations

27 papers · 1.5k indexed · 1 hit paper · h-index 15

Impact in

Biological Psychiatry top 2%
- Tryptophan and brain disorders
Psychiatry and Mental health top 1%
- Migraine and Headache Studies
- Schizophrenia research and treatment

Papers in

Biological Psychiatry 4
- Tryptophan and brain disorders 4
Statistics and Probability 9
- Statistical Methods in Clinical Trials 9

Co-authors: Bruce J. Kinon Byung‐Kun Kim Michael H. Ossipov Vladimir Skljarevski Manjit MatharuLu ZhangAlex Dmitrienko Sara Kollack‐Walker
Journals: Schizophrenia Research (3 papers)BMC Psychiatry (2 papers)Journal of Biopharmaceutical Statistics (2 papers)Journal of Psychopharmacology (2 papers)Biological Psychiatry (1 paper)
Partner nations: United States United Kingdom Italy

In The Last Decade

Brian A. Millen

27 papers receiving 1.5k citations

Hit Papers

align trajectories log scale

Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial 2018 · 375 citations

Peers

Countries citing papers authored by Brian A. Millen

Since Specialization

Citations

This map shows the geographic impact of Brian A. Millen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian A. Millen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian A. Millen more than expected).

Fields of papers citing papers by Brian A. Millen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian A. Millen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian A. Millen. The network helps show where Brian A. Millen may publish in the future.

Co-authors

The 25 scholars most cited alongside Brian A. Millen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Brian A. Millen Line = papers co-authored together Brian A. Millen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Surrogate Endpoints in Drug Development: A Review of Statistical and Regulatory Perspectives and Applications Wiley Interdisciplinary Reviews Computational Statistics ·Tianle Chen, Ying Tian, Brian A. Millen	2025	1
2	A Placebo-Controlled Study of Galcanezumab in Patients with Episodic Cluster Headache: Results from the 8-Week Double-Blind Treatment Phase (Plen02.004) Neurology ·Jennifer Bardos, Peter J. Goadsby, David W. Dodick, Massimo Leone, Tina M. Oakes, James M. Martinez, Brian A. Millen, Chunmei Zhou, Sherie A. Dowsett, Sheena K. Aurora, Liliana Zelada Ruck, Robert R. Conley	2019	2
3	Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies Headache The Journal of Head and Face Pain ·Holland C. Detke, Brian A. Millen, Qi Zhang, Ni Mengxiang, Jessica Ailani, David W. Dodick, Sheena K. Aurora	2019	39
4	Trial of Galcanezumab in Prevention of Episodic Cluster Headache New England Journal of Medicine ·Peter J. Goadsby, David W. Dodick, Massimo Leone, Jennifer Bardos, Tina M. Oakes, Brian A. Millen, Chunmei Zhou, Sherie A. Dowsett, Sheena K. Aurora, Andrew H. Ahn, 徹森池, Robert R. Conley, James M. Martinez	2019	166
5	Multiplicity considerations in subgroup analysis Statistics in Medicine ·Alex Dmitrienko, Brian A. Millen, Ilya Lipkovich	2017	21
6	Serotonin 2A Receptor SNP rs7330461 Association with Treatment Response to Pomaglumetad Methionil in Patients with Schizophrenia Journal of Personalized Medicine ·Laura Nisenbaum, 桑名正隆, Fangyi Zhao, Brian A. Millen, Leanne Munsie, Bruce J. Kinon, David H. Adams, Juan Carlos Gómez, Michelle A. Penny	2016	14
7	Exploratory Analysis for a Targeted Patient Population Responsive to the Metabotropic Glutamate 2/3 Receptor Agonist Pomaglumetad Methionil in Schizophrenia Biological Psychiatry ·Bruce J. Kinon, Brian A. Millen, Lu Zhang, David L. McKinzie	2015	125
8	Multipopulation Tailoring Clinical Trials: Design, Analysis, and Inference Considerations Therapeutic Innovation & Regulatory Science ·Brian A. Millen, Alex Dmitrienko, Sumithra J. Mandrekar, Zongjun Zhang, Артем Владимирович Иванчин	2014	5
9	A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia BMC Psychiatry ·AnnCatherine M. Downing, Bruce J. Kinon, Brian A. Millen, Lu Zhang, Lin Liu, Morozova Ma, Ronald Brenner, R. DALLAGO, Laura Nisenbaum, Fangyi Zhao, Juan Carlos Gómez	2014	93
10	Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison SHILAP Revista de lepidopterología ·David H. Adams, Lu Zhang, Brian A. Millen, Bruce J. Kinon, Marko Šuste	2014	59
11	Bayesian Assessment of the Influence and Interaction Conditions in Multipopulation Tailoring Clinical Trials Journal of Biopharmaceutical Statistics ·Brian A. Millen, Alex Dmitrienko, 黄兵兵	2014	13
12	Pomaglumetad methionil: No significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo Schizophrenia Research ·Virginia L. Stauffer, Brian A. Millen, Scott W. Andersen, Bruce J. Kinon, E. Giffon, Jean‐Pierre Lindenmayer, Juan Carlos Gómez	2013	102
13	A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia BMC Psychiatry ·David H. Adams, Bruce J. Kinon, Simin Baygani, Brian A. Millen, C. R. Greene, Sara Kollack‐Walker, David P. Walling	2013	90
14	Comparison of Long-Term (At Least 24 Weeks) Weight Gain and Metabolic Changes Between Adolescents and Adults Treated with Olanzapine Journal of Child and Adolescent Psychopharmacology ·Ludmila Kryzhanovskaya, Wen Xu, Brian A. Millen, Nayan Acharya, Richards, Olawale Osuntokun	2012	38
15	A Statistical Framework for Decision Making in Confirmatory Multipopulation Tailoring Clinical Trials Drug Information Journal ·Brian A. Millen, Alex Dmitrienko, Stephen J. Ruberg, Lei Shen	2012	27
16	A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia Journal of Clinical Psychopharmacology ·Bruce J. Kinon, Lu Zhang, Brian A. Millen, Olawale Osuntokun, David Schuette, Sara Kollack‐Walker, Kimberley Jackson, Ludmila Kryzhanovskaya, Michał Bieńkowski	2011	190
17	Development of gatekeeping strategies in confirmatory clinical trials Biometrical Journal ·Alex Dmitrienko, Brian A. Millen, Thomas Brechenmacher, Gautier Paux	2011	32
18	Chain Procedures: A Class of Flexible Closed Testing Procedures With Clinical Trial Applications Statistics in Biopharmaceutical Research ·Brian A. Millen, Alex Dmitrienko	2011	37
19	Three Methods for Constructing Parallel Gatekeeping Procedures in Clinical Trials Journal of Biopharmaceutical Statistics ·Alex Dmitrienko, Julia N. Soulakova, Brian A. Millen	2011	11
20	Weight changes over time in adults treated with the oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trials Journal of Psychopharmacology ·Brian A. Millen, Simon Pierre Eyene Ntsama, Charles M. Beasley	2010	19

About Brian A. Millen

Brian A. Millen is a scholar working on Biological Psychiatry, Statistics and Probability, Psychiatry and Mental health, Biochemistry and Physiology, having authored 27 papers that have together received 1.5k indexed citations. Recurring topics across this work include Schizophrenia research and treatment (10 papers), Statistical Methods in Clinical Trials (9 papers), Diet and metabolism studies (7 papers), Health Systems, Economic Evaluations, Quality of Life (6 papers), Bipolar Disorder and Treatment (5 papers), Migraine and Headache Studies (4 papers), Tryptophan and brain disorders (4 papers) and Optimal Experimental Design Methods (3 papers). The work is most often cited by research in Biological Psychiatry (151 citations), Psychiatry and Mental health (818 citations), Cellular and Molecular Neuroscience (512 citations), Pathology and Forensic Medicine (423 citations) and Statistics and Probability (128 citations). Brian A. Millen has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include Bruce J. Kinon, Byung‐Kun Kim, Michael H. Ossipov, Vladimir Skljarevski, Manjit Matharu, Lu Zhang, Alex Dmitrienko, Sara Kollack‐Walker, Olawale Osuntokun and David L. McKinzie. Their work appears in journals such as Schizophrenia Research, BMC Psychiatry, Journal of Biopharmaceutical Statistics, Journal of Psychopharmacology and Biological Psychiatry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact